Global Industry & Regulatory Leaders Join Aegros as Commercial Future Nears
- Global Plasma Industry Expert, Jan M Bult, has been appointed to Chair the company’s advisory body.
- Former Chair of the National Blood Authority (NBA), Gayle Ginnane has also been appointed to the company’s advisory body.
- The body will advise the Founders as the company prepares for its first therapeutic product registration, commercial operations, and possible IPO.
Aegros today is announcing a further senior appointment to its Strategic Advisory Committee (SAC) and the appointment of a committee Chair to advise the company as it prepares both a dossier for submission of its first therapeutic product onto the Australian Register of Therapeutic Goods and completes the upgrade of its dedicated hyperimmune production facility in readiness for commercial sales.
At the inaugural meeting of the SAC, former President and CEO of the Plasma Protein Therapeutics Association (PPTA) for 23 years, Mr Jan M Bult was appointed Chair of the SAC. Originally joining the SAC in 2023, as Chair Mr Bult’s extensive knowledge and understanding of the global plasma market, will be valuable to the company at a time when Aegros has signed Letters of Agreement for facilities to be built in Springfield, Queensland and in Singapore.
Mr Bult said today that “Aegros and its Haemafrac® technology bring something completely new to the plasma sector and I am looking forward to ensuring that its therapies, processes, and technologies are given every chance to succeed in a sector that still relies on old technology.
“The world needs more plasma medicines and Aegros’ strategic roadmap offers a pathway to both meet the world’s unmet need and to make the medicines we will need tomorrow in a virus-prone future,” Mr Bult concluded.
In addition, Aegros has also today announced a new appointee to its SAC, with Former Chair of the National Blood Authority (NBA) Ms Gayle Ginnane also joining the body.
Ms Ginnane’s health governance expertise also includes current appointments at organisations such as Cancer Australia and the Office of the Inspector General of Aged Care, and various other Chief Executive, Director and Chair roles in both government and private sector across the health sectors.
Ms Ginnane said today that “This is an ideal time to bring my experience in governance to Aegros and its decision-making. With demand growing both here and abroad at around 8 per cent, Australia and the world needs a new supplier to meet current and blood product future need. I look forward to being a part of its exciting and emerging leadership with its yield-leading Haemafrac® process, and bringing new therapies to market.”
Also sitting on the Aegros SAC is Dr Erin Evans, CEO of Life Sciences Queensland, who along with Mr Bult was appointed on 23 November 2023.
The SAC convened at the same time the company readies its submission dossier, to include its first therapeutic product onto the Australia Register of Therapeutic Goods.
Co-founder of Aegros, Mr John Manusu said today that “Based on the previously released interim clinical trial results of our hyperimmune against Covid-19, and the progress of the upgrade to our dedicated hyperimmune facility to 100,000 litres capacity, we are ready for commercial operations. The SAC brings together a range of skillsets and expertise we need at this critical time and we look forward to receiving their contributions.”
Co-founder of Aegros, Professor Hari Nair, also said today that “We are thrilled to be joined by such eminent voices as Mr Bult, Ms Ginnane, and Dr Evans on our Advisory Committee. Aegros is in an enviable position; with our patent-pending Haemafrac® and the therapies we can produce – such as our hyperimmune against Covid-19 – we are able to make a difference both globally and to Australia’s immunocompromised patients. Both John and I look forward to working with our SAC, to unleash the potential of our innovations.”
Mr Dave Sharma, who was appointed in 2023 as the SAC’s original Chair has resigned on being elected to the senate. Aegros wishes Mr Sharma all the best for his political career and thanks him for all his support and advice in the past.
What’s next?
- A submission to the Therapeutic Goods Administration (TGA) for an assessment of Aegros’ COVID-19 Hyperimmune will be finalised and lodged during Q2, 2024
About us:
Aegros is an Australian technology leader in the therapeutic plasma market that is projected to exceed US$40B global by 2030. Its GMP licensed Haemafrac® lifts process yields to over 85%, reducing cost and carbon emissions while enhancing product safety.
Aegros is designing, constructing, validating and operating a 1 million litre Haemafrac® facility with support from the Queensland Government which is expected to come online in 2026. This Haemafrac® facility will produce Albumin, IVIG and other plasma products for the Australian and overseas markets.
Contact details:
Karl Wolfenden @ Aegros: +61 400 327 964 karl.wolfenden@aegros.com.au